GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » EBITDA Margin %

SIGY (Sigyn Therapeutics) EBITDA Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sigyn Therapeutics's EBITDA for the three months ended in Sep. 2024 was $-0.83 Mil. Sigyn Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Sigyn Therapeutics's EBITDA margin for the quarter that ended in Sep. 2024 was 0.00%.


Sigyn Therapeutics EBITDA Margin % Historical Data

The historical data trend for Sigyn Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics EBITDA Margin % Chart

Sigyn Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,225.17 - - - -

Sigyn Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sigyn Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Sigyn Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sigyn Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Sigyn Therapeutics's EBITDA Margin % falls into.


;
;

Sigyn Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Sigyn Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-2.093/0
= %

Sigyn Therapeutics's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-0.832/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sigyn Therapeutics  (OTCPK:SIGY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Sigyn Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sigyn Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.
Executives
Joseph Segelman director, 10 percent owner, officer: President & CEO 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp 10 percent owner 9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman director, officer: Secretary 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212